These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38336262)

  • 1. Impact of elexacaftor/tezacaftor/ivacaftor on respiratory colonization in an adult cystic fibrosis clinic.
    Szabo MM; Foushee SE; McPheeters CM; O'Hagan AR; Ramirez AM; O'Reilly EA
    Am J Med Sci; 2024 May; 367(5):337-342. PubMed ID: 38336262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis.
    Dittrich AM; Sieber S; Naehrlich L; Burkhart M; Hafkemeyer S; Tümmler B;
    Int J Infect Dis; 2024 Feb; 139():124-131. PubMed ID: 38036261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
    Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
    Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
    Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
    Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
    Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
    J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
    Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J
    Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 10. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.
    Lonabaugh K; Li G; List R; Huang R; James A; Barros A; Somerville L; Albon D
    Pharmacotherapy; 2024 Mar; 44(3):231-240. PubMed ID: 38143243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    James A; Li G; List R; Lonabaugh K; Smith AD; Barros A; Somerville L; Albon D
    Pediatr Pulmonol; 2024 Mar; 59(3):669-678. PubMed ID: 38088203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
    Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
    J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.
    Bec R; Reynaud-Gaubert M; Arnaud F; Naud R; Dufeu N; Di Bisceglie M; Coiffard B; Gaubert JY; Bermudez J; Habert P
    Eur J Radiol; 2022 Sep; 154():110421. PubMed ID: 35772339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
    Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
    Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
    Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
    Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.